SCHEMBL25801910

SCHEMBL25801910

C=C(Cc1nc(Cc2ccc(OCCCC)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ PLA2G2A P14555 2/20 0.39
▸ LMNA P02545 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.35
▸ PPARG P37231 1/20 0.35
▸ NR1H2 P55055 1/20 0.35
▸ PPARD Q03181 1/20 0.35
▸ PPARA Q07869 1/20 0.35
▸ NR1H3 Q13133 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801788 0.90 ALDH1A1 (0.36) MAPTSMN1; SMN2HSD17B10ALDH1A1PPARG
SCHEMBL25801811 0.89 ALDH1A1 (0.37) ALDH1A1
SCHEMBL25801971 0.88 MAPT (0.35) MAPTKDM4EHDAC6ALDH1A1
SCHEMBL23578251 0.86 MAPT (0.45) MAPTKDM4ECYP1A2CYP2D6PDE4A
SCHEMBL23578189 0.85 MAPT (0.38) MAPTPPARGPPARDPPARA
SCHEMBL23578363 0.85 KMT2A (0.35) MAPTHDAC6LMNAALDH1A1PPARG
SCHEMBL23578197 0.84 MAPT (0.47) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL23578571 0.84 MAPT (0.35) MAPTHDAC6ALDH1A1
SCHEMBL23578414 0.84 TP53 (0.38) MAPTCYP1A2SMN1; SMN2HDAC6LMNA
SCHEMBL23588077 0.84 ACACB (0.52) MAPTSMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 — — EP disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 MAPT 4683/4885KDM4E 1568/4885CYP1A2 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback